What a difference a year makes. From scantily clad women, to a major push for gender diversity, the biopharma industry has undergone a sharp change in the past year alone. According to Fortune Magazine, more than “100 biopharma executives from major drug makers like Eli Lilly (LLY, -0.27%), Johnson & Johnson (JNJ, +0.30%), Bayer, Novartis (NVS, -0.46%), and a slew of biotech CEOs have signed an open letter advocating strategies to get more women involved in the life sciences.”
This comes as huge news as the male dominated industry is now pledging to utilize its resources to expand the life science towards other genders. The letter included 5 Guiding Principles to help establish better processes for diversity as well as a Top Ten Best Practices list for increasing gender diversity (both can be seen HERE)
Within the science and technology fields, achieving gender balance is always a challenge. This is a great first step in moving towards that balance and I am excited to see what’s next for the industry.
http://fortune.com/2017/01/11/biopharma-jpm-gender-diversity-letter/
